Search Results - (Author, Cooperation:M. Pitzalis)

Showing 1 - 3 results of 3, query time: 0.10s Refine Results
  1. 1
    Corsiero, E., Jagemann, L., Perretti, M., Pitzalis, C., Bombardieri, M.
    The American Association of Immunologists (AAI)
    Published 2018
    Staff View
    Publication Date:
    2018-08-21
    Publisher:
    The American Association of Immunologists (AAI)
    Print ISSN:
    0022-1767
    Electronic ISSN:
    1550-6606
    Topics:
    Medicine
    Published by:
    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Staff View
    Publication Date:
    2013-08-03
    Publisher:
    American Association for the Advancement of Science (AAAS)
    Print ISSN:
    0036-8075
    Electronic ISSN:
    1095-9203
    Topics:
    Biology
    Chemistry and Pharmacology
    Computer Science
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Adult ; Chromosomes, Human, Y/*classification/*genetics ; European Continental Ancestry Group/*genetics ; *Evolution, Molecular ; Haplotypes ; Humans ; Italy ; Male ; Phylogeny ; Polymorphism, Single Nucleotide
    Published by:
    Latest Papers from Table of Contents or Articles in Press
  3. 3
    Staff View
    ISSN:
    1365-2036
    Source:
    Blackwell Publishing Journal Backfiles 1879-2005
    Topics:
    Medicine
    Notes:
    Aim:  To explore the efficacy and safety of the topically acting steroid beclometasone dipropionate (BDP) in an oral controlled release formulation in the treatment of extensive or left-sided ulcerative colitis.Methods:  In a multicentre, randomised, parallel-group, single-blind study, patients with active mild to moderate ulcerative colitis were randomised to a 4-week treatment with BDP 5 mg/day o.d. vs. 5-ASA 0.8 g t.d.s. The primary efficacy variable was the decrease of Disease Activity Index (DAI) (clinical symptoms and endoscopic appearance of mucosa). Safety was evaluated by monitoring adverse events, vital signs, haematochemical parameters and adrenal function.Results:  One hundred and seventy-seven patients were enrolled and randomly treated with BDP (n = 90) or 5-ASA (n = 87). Mean DAI score decreased in both treatments groups (P 〈 0.0001 vs. baseline for both groups). Clinical remission was achieved in 63.0% of patients in the BDP group vs. 62.5% in the 5-ASA group. A significant DAI score improvement (P 〈 0.05) in favour of BDP was observed in patients with extensive disease. Both treatments were well tolerated. Mean plasma cortisol levels were significantly reduced vs. baseline in BDP recipients, but without signs of pituitary–adrenal function depletion.Conclusion:  Oral BDP gave an overall treatment result in patients with active ulcerative colitis without signs of systemic side-effects.
    Type of Medium:
    Electronic Resource
    URL:
    Articles: DFG German National Licenses